AEON — AEON Biopharma, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1837607 ·
Last close
$0.26
Market Cap
$13.05M
52W High
$1.45
52W Low
$0.18
ADV30
11,178,422
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,929,000 | -1,155,000 | 5,910,000 | 3,431,000 | 21,271,000 |
| Mar 2026 | 0 | — | -5,937,000 | -11,793,000 | 8,630,000 | 6,243,000 | 25,382,000 |
| Dec 2025 | 0 | — | -5,501,000 | -37,137,000 | 5,560,000 | 3,006,000 | 60,587,000 |
| Sep 2025 | 0 | — | -2,530,000 | -4,538,000 | 8,734,000 | 5,927,000 | 28,606,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,035,000
Investing CF
$0
Financing CF
$7,832,000
CapEx
$-4,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.00
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-482,612,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-18,290,000
Pretax Income TTM
$-60,110,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,302,000 | -39,222,000 | 5,560,000 | 60,587,000 | -55,027,000 | -17,308,000 |
| Dec 2024 | 0 | -27,824,000 | 42,005,000 | 3,142,000 | 31,711,000 | -28,569,000 | -20,292,000 |
| Dec 2023 | — | — | — | 6,845,000 | 159,889,000 | -153,044,000 | — |
| Dec 2022 | 0 | -48,429,000 | -52,556,000 | 10,778,000 | 281,191,000 | -287,500,000 | -35,584,000 |
| Dec 2021 | 0 | -36,881,000 | -55,637,000 | — | — | — | -28,433,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-24,737,000
OpCashFlow TTM
$0
Assets (Latest)
$5,560,000
Forward EPS
$-0.27
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIVI | BIOVIE INC. | $13.01M | $1.54 | — |
| VTGN | Vistagen Therapeutics, Inc. | $13.18M | $0.30 | — |
| ANEB | Anebulo Pharmaceuticals, Inc. | $13.26M | $0.32 | — |
| LSTA | LISATA THERAPEUTICS, INC. | $13.52M | $1.50 | — |
| TPST | Tempest Therapeutics, Inc. | $13.75M | $0.83 | — |
News headlines (Yahoo Finance, 1h cache)
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
2026-09-09 12:00 · Yahoo
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
2026-08-24 12:00 · Yahoo
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-12 20:15 · Yahoo
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
2026-08-03 20:15 · Yahoo
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
2026-07-14 12:00 · Yahoo
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
2026-06-04 11:00 · Yahoo
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
2026-04-03 20:05 · Yahoo
AEON Biopharma Sets Annual Shareholder Meeting
2026-04-24 20:05 · Yahoo
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
2026-03-30 20:05 · Yahoo
Cervical Dystonia Market to Witness Robust Growth During the Forecast Period (2026-2036) Driven by the Expanding Therapeutic Options | DelveInsight
2026-06-02 14:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.